One issued patent already reaches beyond the bar.

The patent number is verified against the issued filing on file before this page asserts coverage, the same verification the moat page applies to all four patents.

The single most important thing on this page is what it does not do. It does not sum the size of four industries and call the total a market Klynkz can address. A figure like the entire chemical industry's revenue is the size of an economy, not the size of an inventory-sensing opportunity inside it. Presenting industry GDP as patent TAM reads as unserious to anyone who checks, so this page refuses to. Each vertical is sized bottom-up from the sensing-addressable slice if it is sized at all, and where a bottom-up figure is not yet sourced it is left unstated rather than inflated.

Medical supply is the cleanest adjacency because it has both a clear sensing fit and a clear regulatory pull. Hospitals and clinics must track high-value and controlled supplies with chain-of-custody and par-level accuracy, which is exactly the problem the mat solves for bottles. The same hardware, with new software and FDA-grade compliance, reads medical inventory the way it reads liquor.

If a single expansion vertical is sized for investors, medical chain-of-custody is the one to size, bottom-up from the sensing-addressable slice and labeled a future-phase option gated on hospitality proof. The bottom-up figure is [pending source verification] and is not asserted until sourced.

Military and government asset tracking is the vertical explicitly named in the patent filing, which makes it the most strategically grounded of the four. Defense and government agencies already buy RFID and IoT asset-visibility systems through established procurement channels, so the adjacency is to a real, existing line of spend rather than a hypothetical one.

The credible figure for this vertical is the RFID and IoT asset-visibility line of government spend, not the defense budget as a whole. That bottom-up figure is [pending source verification].

Chemical inventory and reagent tracking is a genuine adjacency: the mat reads containers of regulated substances the same way it reads bottles, and regulatory mandates can drive adoption. It is also the vertical where the discipline of this page matters most. The size of the global chemical industry is not the size of the sensing opportunity within it, and this page does not present industry revenue as a market. The sensing-addressable slice is orders of magnitude smaller, and only that slice is relevant.

The bottom-up sensing-addressable figure for chemical inventory tracking is [pending source verification] and is not asserted until sourced.

Retail and parts inventory is the broadest adjacency and the one requiring the least new research, because the same sensor technology reads parts and packaged goods with minimal modification. It is also the vertical where the market-size-versus-addressable-slice error is easiest to make, so it carries the same discipline: the relevant figure is the sensing- addressable inventory-management slice, not the size of the retail or parts market.

The bottom-up sensing-addressable figure for retail and parts is [pending source verification].

The expansion verticals are deliberately the last opportunity an investor reads, not the first. Placed early, a cross-vertical figure reads as a TAM trap and costs credibility. Placed late, after the disciplined hospitality case is fully built, it reads as genuine granted optionality, because the investor already trusts the rest. The expansion is a granted patent, not a projection, and the section earns the right to mention it only after proving the core.

flowchart LR
    H["Hospitality core
proven, sized, sourced"] --> P["Hospitality proof at scale
the raise funds this"]
    P --> O{"Then, and only then,
exercise an option?"}
    O -- "regulatory pull is clear" --> M["Medical chain-of-custody"]
    O -- "named in the filing" --> G["Military and government"]
    O -- "mandate-driven" --> C["Chemical"]
    O -- "lowest R&D" --> R["Retail and parts"]

Each branch is an option the company can exercise once hospitality is won, sequenced by how clean the pull and the sensing fit are. None of them is funded by this round or required by the model. They are the upside that the issued patent makes credible.

The expansion narrative is valuable precisely because it is disciplined. One issued patent covers four credible adjacent verticals. Each is framed as a granted option, sized bottom-up by its sensing-addressable slice where a sourced figure exists and left unsized where it does not. None of them carries the valuation, which rests on hospitality. That is a stronger story than a headline market figure, because it survives the questions a sophisticated investor asks.